Iris Schrader

4.3k total citations · 1 hit paper
27 papers, 2.2k citations indexed

About

Iris Schrader is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Iris Schrader has authored 27 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 17 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Iris Schrader's work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (9 papers). Iris Schrader is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (9 papers). Iris Schrader collaborates with scholars based in Germany, Switzerland and Austria. Iris Schrader's co-authors include Gϋnter von Minckwitz, Sibylle Loibl, Martina Komor, Marc Roller, Christine Solbach, Claus Hanusch, Carsten Denkert, Silvia Darb‐Esfahani, Knut Engels and Jan Budczies and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Iris Schrader

25 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

2009 1.3k citations Carsten Denkert, Sibylle Loibl et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iris Schrader Germany	12	1.8k	874	592	398	335	27	2.2k
Martina Komor Germany	15	1.6k 0.9×	744 0.9×	668 1.1×	352 0.9×	586 1.7×	25	2.5k
Vidya Maiya Switzerland	7	1.4k 0.8×	531 0.6×	433 0.7×	484 1.2×	255 0.8×	13	1.7k
Eva Muñoz‐Couselo Spain	20	1.6k 0.9×	446 0.5×	574 1.0×	418 1.1×	598 1.8×	89	2.1k
Christian von Törne Germany	7	1.5k 0.8×	559 0.6×	751 1.3×	250 0.6×	497 1.5×	8	2.0k
Petros Nikolinakos United States	20	1.5k 0.8×	869 1.0×	404 0.7×	986 2.5×	628 1.9×	51	2.4k
Min Hye Jang South Korea	20	1.0k 0.6×	473 0.5×	303 0.5×	279 0.7×	610 1.8×	42	1.7k
Ursina Teitelbaum United States	19	1.9k 1.1×	452 0.5×	1.2k 2.0×	279 0.7×	596 1.8×	54	2.7k
Artur Mezheyeuski Sweden	22	1.0k 0.6×	474 0.5×	542 0.9×	391 1.0×	796 2.4×	64	1.9k
Gert Van den Eynden Belgium	17	861 0.5×	381 0.4×	445 0.8×	289 0.7×	400 1.2×	34	1.3k
Stephen J. Luen Australia	13	958 0.5×	307 0.4×	453 0.8×	354 0.9×	290 0.9×	32	1.3k

Countries citing papers authored by Iris Schrader

Since Specialization

Citations

This map shows the geographic impact of Iris Schrader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Schrader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Schrader more than expected).

Fields of papers citing papers by Iris Schrader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Schrader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Schrader. The network helps show where Iris Schrader may publish in the future.

Co-authorship network of co-authors of Iris Schrader

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Schrader. A scholar is included among the top collaborators of Iris Schrader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Schrader. Iris Schrader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Siggelkow, Wulf, Iris Schrader, S Noeding, et al.. (2020). First Prospective Cross-Sectional Study on the Impact of Immigration Background and Education in Early Detection of Breast Cancer. Breast Care. 16(5). 516–522. 3 indexed citations

Wuerstlein, Rachel, Nadia Harbeck, Eva‐Maria Grischke, et al.. (2020). Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. Breast Care. 16(1). 50–58.

Riethdorf, Sabine, Volkmar Müller, Sibylle Loibl, et al.. (2017). Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clinical Cancer Research. 23(18). 5384–5393. 82 indexed citations

Gerber, Bernd, Gϋnter von Minckwitz, Holger Eidtmann, et al.. (2014). Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). Annals of Surgical Oncology. 21(8). 2517–2524. 16 indexed citations

Loibl, Sibylle, Bettina Conrad, Nadia Harbeck, et al.. (2014). Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*. Breast Care. 9(3). 169–174. 10 indexed citations

Harbeck, Nadia, Matthias W. Beckmann, Achim Rody, et al.. (2013). HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care. 8(1). 49–55. 84 indexed citations

Lück, Hans‐Joachim, Andreas du Bois, Sibylle Loibl, et al.. (2013). Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Research and Treatment. 139(3). 779–787. 19 indexed citations

Gerber, B., Sibylle Loibl, Holger Eidtmann, et al.. (2013). Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Annals of Oncology. 24(12). 2978–2984. 105 indexed citations

Neugebauer, Julia, Ulrich Andergassen, Bernadette Jaeger, et al.. (2013). Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study.. Journal of Clinical Oncology. 31(15_suppl). 11042–11042. 2 indexed citations

10.

Schrader, Iris, Andreas Schneeweiß, Matthias Geberth, et al.. (2012). Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study.. Journal of Clinical Oncology. 30(15_suppl). 1077–1077.

11.

Minckwitz, Gϋnter von, Silvia Darb‐Esfahani, Sibylle Loibl, et al.. (2011). Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40). Breast Cancer Research and Treatment. 132(3). 863–870. 35 indexed citations

12.

Eidtmann, Holger, K. Kittel, Mahdi Rezai, et al.. (2011). P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab.. Cancer Research. 71(24_Supplement). P1–14. 2 indexed citations

13.

Gerber, B., Holger Eidtmann, Peter A. Fasching, et al.. (2011). Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44).. Journal of Clinical Oncology. 29(15_suppl). 1006–1006. 23 indexed citations

14.

Riethdorf, Sabine, Volkmar Müller, Liling Zhang, et al.. (2010). Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clinical Cancer Research. 16(9). 2634–2645. 398 indexed citations

15.

Riethdorf, Sabine, Volkmar Mueller, Thomas Rau, et al.. (2010). Abstract PD04-06: Changes in Circulating Tumor and Endothelial Cells in Peripheral Blood of Patients Treated in the Neoadjuvant Chemotherapy Plus Targeted Treatment Breast Cancer Study “GeparQuinto”. Cancer Research. 70(24_Supplement). PD04–6. 8 indexed citations

16.

Kaufmann, M., Nicolaì Maass, Serban Dan Costa, et al.. (2010). First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. European Journal of Cancer. 46(18). 3184–3191. 30 indexed citations

17.

Kaufmann, M., Marc Sütterlin, Iris Schrader, et al.. (2009). 5002 MoniCa: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer (GBG39). European Journal of Cancer Supplements. 7(2). 260–260. 4 indexed citations

18.

Denkert, Carsten, Sibylle Loibl, Aurelia Noske, et al.. (2009). Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology. 28(1). 105–113. 1295 indexed citations breakdown →

19.

Schindlbeck, Christian, Andreas Schneeweiß, Iris Schrader, et al.. (2009). 5168 Circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after primary diagnosis – Results from the German SUCCESS trial. European Journal of Cancer Supplements. 7(2). 310–311. 1 indexed citations

20.

Mueller, Volkmar, Sabine Riethdorf, Sibylle Loibl, et al.. (2007). Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—A translational project of the German Breast Group study GeparQuattro. Journal of Clinical Oncology. 25(18_suppl). 21085–21085. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact